Stevanato Group (STVN) AI Stock Analysis

• Market Cap: $6.82B
• Dividend Yield: 0.25%
• Average Volume (3M): 292.33K
• Price to Earnings (P/E): 46.7
• Beta (1Y): 0.70
• Revenue Growth: 5.95%
• EPS Growth: 7.73%
• Country: US
• Employees: 5,521
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.16
• Shares Outstanding: 49,604,650
• 10 Day Avg. Volume: 241,134
• 30 Day Avg. Volume: 292,333
• PEG Ratio: -2.23
• Price to Book (P/B): 4.09
• Price to Sales (P/S): 5.20
• P/FCF Ratio: -36.39
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $27.00
• Price Target Upside: 10.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $26.00 ▲(6.51% Upside)

Stevanato Group's overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting revenue growth and strategic investments. However, technical indicators suggest a bearish trend, and the stock's high valuation poses a risk. Addressing cash flow challenges and Engineering segment issues will be crucial for future performance.

Positive Factors

Revenue Growth

The consistent revenue growth, particularly in high-value solutions, indicates strong market demand and effective product positioning, supporting long-term business expansion.

Capacity Expansion

Investments in capacity expansion enhance the company's ability to meet increasing demand, positioning it for sustained growth in the pharmaceutical packaging market.

High-Value Solutions

The significant growth in high-value solutions highlights the company's innovation and ability to capture premium market segments, ensuring competitive advantage.

Negative Factors

Cash Flow Challenges

Persistent cash flow issues could hinder the company's ability to invest in growth opportunities and maintain financial flexibility, impacting long-term stability.

Engineering Segment Decline

The decline in the Engineering segment suggests operational inefficiencies and challenges in converting opportunities, potentially affecting overall profitability.

Foreign Currency Headwinds

Currency fluctuations pose a risk to revenue stability, potentially affecting financial performance and requiring strategic hedging to mitigate impacts.

Stevanato Group Business Overview & Revenue Model

Company Description

Stevanato Group (STVN) is a leading global provider of integrated solutions for the pharmaceutical and biotechnology sectors, specializing in the design and manufacturing of glass primary packaging and drug delivery systems. The company operates in two main segments: Glass & Devices, which includes the production of vials, syringes, and cartridges, and Engineering, which offers a range of services including the development of automated systems for the pharmaceutical industry. Stevanato Group is committed to innovation, quality, and sustainability, providing advanced solutions that support the safe and effective delivery of medications.

How the Company Makes Money

Stevanato Group generates revenue primarily through the sale of its glass packaging products and drug delivery systems to pharmaceutical and biotech companies. Key revenue streams include the manufacturing and sale of vials, syringes, and cartridges, which are critical for the storage and delivery of injectable drugs. Additionally, the company offers engineering services, including the design and implementation of automated systems for drug packaging and delivery, which further contributes to its earnings. Significant partnerships with major pharmaceutical companies enhance its revenue potential, as these collaborations often lead to long-term contracts and increased demand for its products. The company also benefits from a growing global demand for biologics and personalized medicine, which drives the need for innovative packaging solutions.

Stevanato Group Financial Statement Overview

Summary

Stevanato Group demonstrates strong revenue growth and operational efficiency, with stable margins and a solid balance sheet. However, cash flow challenges, particularly negative free cash flow, could pose risks if not addressed. The company should focus on improving cash flow management to support its growth trajectory and maintain financial stability.

Income Statement

Stevanato Group shows a solid revenue growth trajectory, with a TTM revenue growth rate of 1.82% and consistent annual growth. The gross profit margin is stable at 28.04% TTM, indicating effective cost management. However, the net profit margin has slightly decreased to 11.75% TTM from previous years, suggesting some pressure on net income. Overall, the company maintains healthy EBIT and EBITDA margins, reflecting operational efficiency.

Balance Sheet

The balance sheet is strong with a manageable debt-to-equity ratio of 0.30 TTM, indicating low leverage. Return on equity is moderate at 9.71% TTM, showing decent profitability relative to shareholder equity. The equity ratio stands at a healthy level, suggesting a stable financial structure. However, the slight increase in debt over the years could be a point of concern if it continues.

Cash Flow

The cash flow statement reveals challenges, with a negative free cash flow growth rate of -34.96% TTM, indicating cash flow issues. The operating cash flow to net income ratio is 0.43 TTM, showing that operating cash flow covers net income adequately. However, the negative free cash flow to net income ratio suggests that the company is not generating sufficient free cash flow relative to its net income, which could impact future investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.15B	1.10B	1.09B	983.68M	843.92M	662.04M
Gross Profit	321.07M	302.32M	339.89M	319.80M	265.40M	194.18M
EBITDA	304.88M	247.80M	272.35M	256.40M	226.93M	156.38M
Net Income	134.56M	117.78M	145.63M	142.85M	134.32M	78.51M
Balance Sheet
Total Assets	2.35B	2.33B	2.07B	1.66B	1.42B	967.98M
Cash, Cash Equivalents and Short-Term Investments	94.17M	98.27M	70.35M	256.65M	438.21M	157.12M
Total Debt	414.95M	428.97M	396.59M	218.37M	244.29M	363.01M
Total Liabilities	953.42M	924.43M	938.93M	663.79M	577.18M	657.84M
Stockholders Equity	1.40B	1.40B	1.13B	996.13M	842.07M	310.50M
Cash Flow
Free Cash Flow	-142.79M	-157.79M	-336.72M	-139.81M	20.16M	59.65M
Operating Cash Flow	300.52M	155.78M	105.21M	103.31M	133.34M	155.66M
Investing Cash Flow	-440.59M	-310.21M	-421.22M	-242.95M	-96.43M	-96.09M
Financing Cash Flow	81.18M	183.22M	158.03M	-44.54M	254.85M	-26.52M

Stevanato Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Negative. The current price of 24.41 is below the 20-day moving average (MA) of 25.10, below the 50-day MA of 25.32, and above the 200-day MA of 23.17, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 24.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STVN.

Stevanato Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	78 Outperform	$5.25B	44.58	8.30%	―	11.49%	-2.89%
LMAT	70 Outperform	$1.95B	41.90	13.81%	0.89%	14.11%	23.98%
STVN	64 Neutral	$6.82B	46.69	9.55%	0.25%	5.95%	7.73%
RGEN	63 Neutral	$8.21B	5,641.25	0.08%	―	11.74%	―
TFX	60 Neutral	$5.51B	29.37	4.36%	1.09%	1.11%	-23.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATR	50 Neutral	$7.58B	18.52	15.80%	1.58%	2.50%	25.05%

Stevanato Group Corporate Events

Stevanato Group Achieves 9% Revenue Growth in Q3 2025

Stevanato Group reported a 9% increase in revenue for the third quarter of 2025, reaching €303.2 million, with high-value solutions accounting for a record 49% of total revenue. The company’s Biopharmaceutical and Diagnostic Solutions segment drove this growth, offsetting a decline in the Engineering Segment. The financial results were bolstered by favorable product shipment timing and increased demand for high-performance Nexa® syringes. Despite challenges such as foreign currency impacts and tariff costs, Stevanato Group maintained its fiscal 2025 guidance, highlighting its strategic investments in capacity expansion and innovation to support future growth.

Stevanato Group Discusses Q3 2025 Financial Results Amid Global Challenges

On November 6, 2025, Stevanato Group held an investor conference call to discuss its Q3 2025 financial results. The company is navigating various challenges, including global supply chain issues and geopolitical tensions, while focusing on expanding its capacity to meet customer demand. Despite these hurdles, Stevanato Group remains committed to optimizing its industrial footprint and enhancing its supply chain strategies, which are crucial for maintaining its competitive edge in the healthcare sector.

Stevanato Group Releases Interim Financial Report for September 2025

Stevanato Group released its interim financial report for the three and nine months ending September 30, 2025, highlighting the company’s performance and strategic initiatives. The report provides insights into the company’s efforts to optimize its industrial footprint and enhance supply chain strategies amidst global economic challenges. The company faces risks related to market competition, supply chain disruptions, and geopolitical tensions, which could impact its operations and financial performance.

Stevanato Group Reports Strong Q2 2025 Growth in Biopharmaceutical Segment

On August 5, 2025, Stevanato Group reported an 8% revenue growth in the second quarter, driven by its Biopharmaceutical and Diagnostic Solutions Segment, despite a decline in its Engineering Segment. The company is advancing its business optimization plan, with new facilities in Latina and Fishers contributing to growth. Stevanato is focusing on expanding its capacity for high-value syringes and enhancing its commercial strategy to capitalize on long-term growth opportunities, including the rise in biologics and self-administration of medicines.